Pangaea Oncology (XMAD:PANG) Total Current Liabilities: €7.25 Mil (As of Dec. 2025)


XMAD:PANG Pangaea Oncology SA XMAD:PANG
60 GF Score
Price €1.57
GF Value €2.16
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology Total Current Liabilities?

Pangaea Oncology XMAD:PANG +3.97% 60 Total Current Liabilities is €7.25 Mil as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 60/100 and a GF Value™ of €2.16 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Pangaea Oncology's total current liabilities for the quarter that ended in Dec. 2025 was €7.25

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Pangaea Oncology Total Current Liabilities Related Terms

Pangaea Oncology Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pangaea Oncology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pangaea Oncology Total Current Liabilities Chart

Pangaea Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.19 2.72 6.86 7.01 7.25

Pangaea Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.86 7.23 7.01 5.73 7.25
XMAD:PANG
60GF Score
Pangaea Oncology SA XMAD:PANG
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pangaea Oncology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Pangaea Oncology's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.525+3.628
+Other Current Liabilities+Current Deferred Liabilities
=0.095999999999999+0
=7.25

Pangaea Oncology's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.525+3.628
+Other Current Liabilities+Current Deferred Liabilities
=0.095999999999999+0
=7.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €7.25 Mil mean?
Pangaea Oncology (XMAD:PANG) has a Total Current Liabilities of €7.25 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Pangaea Oncology and its competitors.
Is Pangaea Oncology's Total Current Liabilities too high?
Pangaea Oncology's current Total Current Liabilities is €7.25 Mil. Overall, Pangaea Oncology has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Total Current Liabilities compare to TMO and DHR?
Pangaea Oncology's Total Current Liabilities of €7.25 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Diagnostics & Research company?
A good Total Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Pangaea Oncology and its competitors. Pangaea Oncology's current Total Current Liabilities is €7.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.16, compared to a current price of €1.57 — trading 27.3% below its estimated fair value. The current Total Current Liabilities is €7.25 Mil. Pangaea Oncology's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Total Current Liabilities is €7.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.57 is trading 27.3% below its estimated GF Value™ of €2.16. GuruFocus considers Pangaea Oncology to be Modestly Undervalued.

Key valuation signals for XMAD:PANG:

  • Total Current Liabilities: €7.25 Mil
  • GF Value™: €2.16 vs. price of €1.57 (27.3% below fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
60GF Score

Get the complete analysis for XMAD:PANG

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.57
Price
€2.16
GF Value